Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

ClinicalTrials.gov 24,857 recruiting now free trial finder

Find a clinical trial that's recruiting now

Search 24,857 actively recruiting US clinical trials by condition, drug, or state, each entry links straight to its NIH ClinicalTrials.gov record so you can check eligibility and contact the study team.

24,857
trials recruiting now
14%
of all US trials open to enrollment
52
states with recruiting sites

A trial is listed as recruiting when its sponsor has marked it open to new participants on the public registry. Type a condition or drug name (for example, "breast cancer" or "pembrolizumab") to narrow the list, and add a state to find studies with a site near you. Results are ordered with the most relevant recruiting studies first; each card shows the study phase and enrollment target, and opens the full record, including eligibility criteria and contact details, on ClinicalTrials.gov.

100 trials found

Recruiting 5,000,000 target

The Pediatric Anesthesia Quality Improvement Project

The Society for Pediatric Anesthesia

NCT00674388

Recruiting 150,000 target

Improving Safety and Quality of Tracheal Intubation Practice in Pediatric ICUs

Children's Hospital of Philadelphia

NCT02493478

Recruiting 50,000 target

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

Massive Bio

NCT03452774

Recruiting NA 36,503 target

Supraglottic Airway for Resuscitation Trial

Children's Hospital of Philadelphia

NCT07150923

Recruiting 34,532 target

Risk of Major Adverse Cardiovascular Events for Naldemedine & Other Medications for Opioid Induced Constipation

BioDelivery Sciences International

NCT03720613

Recruiting 30,000 target

MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles

Agendia

NCT03053193

Recruiting 20,000 target

A Prospective Registry to Enable Collection of Standardized Routine Care Oncology Patient Data

N-Power Medicine

NCT06877884

Recruiting 16,640 target

Tezspire Cardiac Events PASS

AstraZeneca

NCT06951867

Recruiting Phase 3 12,800 target

Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity

Amgen

NCT07037433

Recruiting Phase 2 9,999 target

Safety Study of Unlicensed IND Cord Blood Units Manufactured by the National Cord Blood Program for Unrelated Transplantation

New York Blood Center

NCT01656603

Recruiting 7,000 target

Quality of Pediatric Resuscitation in a Multicenter Collaborative

Children's Hospital of Philadelphia

NCT02708134

Recruiting 6,550 target

Non-Invasive Preeclampsia Screening and Biobank

Sequenom

NCT06643741

Recruiting Phase 3 5,500 target

An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)

AstraZeneca

NCT05952557

Recruiting 5,000 target

Collection and Storage of Tissue and Blood Samples From Patients With Cancer

National Cancer Institute LAO

NCT02474160

Recruiting 5,000 target

Drug-Eluting Registry: Real-World Treatment of Lesions in the Peripheral Vasculature

Boston Scientific Corporation

NCT04674969

Recruiting 5,000 target

Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)

Duke University

NCT04278404

Recruiting 4,000 target

GRANITE: Airsupra Effectiveness in the Real World

AstraZeneca

NCT07141277

Recruiting 3,000 target

ATHN Transcends: A Natural History Study of Non-Neoplastic Hematologic Disorders

American Thrombosis and Hemostasis Network

NCT04398628

Recruiting NA 2,300 target

Cervical Ripening as an Outpatient Method Using the Foley (COMFORT)

University of Pennsylvania

NCT05759988

Recruiting Phase 3 2,130 target

Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2

AstraZeneca

NCT07431281

Recruiting 2,000 target

Development and Validation of a Novel Eye-Tracking Software-based Platform to Extract Oculometric Measures

NeuraLight

NCT05476523

Recruiting Phase 3 1,700 target

A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast

Boehringer Ingelheim

NCT06238622

Recruiting Phase 3 1,656 target

A Study Using Risk Factors to Determine Treatment for Children With Favorable Histology Wilms Tumors (FHWT)

Children's Oncology Group

NCT06401330

Recruiting 1,600 target

National Cancer Institute "Cancer Moonshot Biobank"

National Cancer Institute (NCI)

NCT04314401

Recruiting Phase 3 1,594 target

Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation

European Myeloma Network B.V.

NCT05243797

Recruiting Phase 3 1,590 target

A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma

Janssen Research & Development

NCT05552222

Recruiting NA 1,530 target

Optimal Ventilation for Cardiac Arrest

Children's Hospital of Philadelphia

NCT07114510

Recruiting 1,500 target

Study of the Long-Term Safety and Outcomes of Treating Pulmonary Embolism With the Indigo Aspiration System

Penumbra

NCT04798261

Recruiting Phase 1 1,314 target

Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid Tumors

Exelixis

NCT05176483

Recruiting Phase 3 1,220 target

Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma

AstraZeneca

NCT06921785

Recruiting 1,200 target

Prospective Multicenter Evaluation of a New Predictive Model for the Progression of Adolescent Idiopathic Scoliosis

St. Justine's Hospital

NCT02434003

Recruiting 1,200 target

Deep Neural Network Stratification for Use Detecting Endometriosis in Women Affected by Chronic Pelvic Pain (EndoCheck)

Aspira Women's Health

NCT05245695

Recruiting Phase 3 1,095 target

Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma

Genmab

NCT06191744

Recruiting 1,000 target

University of Delaware Parkinson's Disease Registry

University of Delaware

NCT04496973

Recruiting 1,000 target

National Collaborative to Improve Care of Children With Complex Congenital Heart Disease

Children's Hospital Medical Center, Cincinnati

NCT02852031

Recruiting 1,000 target

Observational, Non-Interventional Study Supporting Validation of VO2Max Estimation Methods Using Results in Patients Receiving Standard of Care Cardiopulmonary Exercise Tests (CPET)

Prolaio

NCT05678530

Recruiting Phase 3 1,000 target

A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)

Merck Sharp & Dohme

NCT07060807

Recruiting 1,000 target

Achieving Understanding of the Natural History of Sickle Cell Trait (AUNT)

National Alliance for Sickle Cell Centers

NCT06071377

Recruiting 1,000 target

BBD Longitudinal Study of Osteogenesis Imperfecta

Baylor College of Medicine

NCT02432625

Recruiting Phase 3 990 target

A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00007)

AstraZeneca

NCT06878261

Recruiting Phase 2 956 target

Study BT8009-230 in Participants With Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2)

BicycleTx Limited

NCT06225596

Recruiting Phase 4 952 target

A Study Comparing Oral Buprenorphine and Injectable Buprenorphine for the Treatment of Opioid Use Disorder

VA Office of Research and Development

NCT04375033

Recruiting Phase 2 920 target

Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study

Hoffmann-La Roche

NCT04589845

Recruiting Phase 2 900 target

Using Biomarker Tests to Select and Test New, Personalized Treatments for Extensive Stage Small Cell Lung Cancer, PRISM Study

SWOG Cancer Research Network

NCT06769126

Recruiting Phase 3 895 target

Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)

AstraZeneca

NCT04862663

Recruiting Phase 3 880 target

A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)

AstraZeneca

NCT06692738

Recruiting Phase 3 878 target

A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Non-squamous NSCLC

AstraZeneca

NCT06627647

Recruiting Phase 3 830 target

A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer

AstraZeneca

NCT06868277

Recruiting 800 target

LOTUS-CC: An Observational Research Study to Uncover Subtypes of Cancer Cachexia

University of Rochester

NCT06073431

Recruiting 796 target

Target Trial Emulation for Pharmacologic Treatment of Neonatal Opioid Withdrawal Syndrome

HELP for NOWS Consortium

NCT07278375

Recruiting Phase 3 795 target

A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide

Janssen Research & Development

NCT06208150

Recruiting Phase 3 770 target

Ketamine add-on Therapy for Established Status Epilepticus Treatment Trial (KESETT)

University of Virginia

NCT06907173

Recruiting Phase 3 750 target

A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)

Amgen

NCT05920356

Recruiting Phase 3 750 target

Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)

Children's Oncology Group

NCT03126916

Recruiting Phase 3 680 target

A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)

Pfizer

NCT07144280

Recruiting Phase 3 668 target

Geriatric Evaluation and Management With Survivorship Health Education for Older Survivors of Cancer, GEM-S Trial

University of Rochester

NCT05006482

Recruiting Phase 3 659 target

Human Menopausal Gonadotropin Research in Infertility Assessing Cumulative Live Birth With Frozen Embryo Transfer.

Granata Bio Corporation

NCT07216742

Recruiting Phase 2 650 target

FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC

Bicara Therapeutics

NCT06788990

Recruiting Phase 3 600 target

Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib

Kartos Therapeutics

NCT06479135

Recruiting NA 600 target

Empowering Young Parents: Building Healthy Relationships Study

RTI International

NCT06576193

Recruiting Phase 2 594 target

A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)

Merck Sharp & Dohme

NCT06890884

Recruiting 581 target

CoMind Early Feasibility Study

CoMind Technologies Limited

NCT06368648

Recruiting 550 target

ARDS in Children and ECMO Initiation Strategies Impact on Neurodevelopment (ASCEND)

University of Michigan

NCT05388708

Recruiting 550 target

A Study in Non-Small Cell Lung Cancer

N-Power Medicine

NCT07174388

Recruiting Phase 1 542 target

A First-in-human, Dose Escalation and Dose Expansion Study of SAR445877 in Adult Participants With Advanced Solid Tumors

Sanofi

NCT05584670

Recruiting Phase 3 540 target

A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open Label Iptacopan/LNP023 in Participants With Primary IgA Nephropathy

Novartis Pharmaceuticals

NCT04557462

Recruiting Phase 3 540 target

Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer

Relay Therapeutics

NCT06982521

Recruiting NA 540 target

Category Learning Retention in Adults With and Without Developmental Language Disorder

University of Delaware

NCT05901493

Recruiting Phase 2 540 target

Dose Range Finding Study to Assess Efficacy and Safety of Tozorakimab in Adults With Uncontrolled Asthma on Medium-to-High Dose Inhaled Corticosteroids

AstraZeneca

NCT06932263

Recruiting 538 target

Prospective Non-Interventional Study Comparing Osimertinib +/- Chemotherapy for EGFR-Mutated NSCLC Patients

PrECOG

NCT06538038

Recruiting Phase 3 528 target

Testing Whether the Addition of Carboplatin Chemotherapy to Cabazitaxel Chemotherapy Will Improve Outcomes Compared to Cabazitaxel Alone in People With Castrate-Resistant Prostate Cancer That Has Spread Beyond the Prostate to Other Parts of the Body

SWOG Cancer Research Network

NCT06470243

Recruiting Phase 3 510 target

OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer

Olema Pharmaceuticals

NCT06016738

Recruiting Phase 3 500 target

Stress Hydrocortisone In Pediatric Septic Shock

Jerry Zimmerman

NCT03401398

Recruiting 500 target

Chronic Postsurgical Pain

Chantel Burkitt

NCT05764681

Recruiting 500 target

Surgical Thromboprophylaxis Practices in Oncology Patients Within the NCORP Network, STOP-VTE Study

Wake Forest University Health Sciences

NCT07215624

Recruiting 500 target

A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS)

TG Therapeutics

NCT06433752

Recruiting Phase 2 500 target

A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)

Bristol-Myers Squibb

NCT06926868

Recruiting Phase 3 500 target

A Study to Evaluate the Safety and Efficacy of BGB-16673 Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

BeOne Medicines

NCT06973187

Recruiting Phase 3 500 target

Pulmonary Embolism - Thrombus Removal With Catheter-Directed Therapy

NYU Langone Health

NCT05591118

Recruiting 500 target

Outcomes in Pediatric and Young Adult B-Cell Malignancies After Commercially Available Immunotherapy

Stanford University

NCT05865301

Recruiting Phase 3 500 target

A Phase 3 Study to Evaluate Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Head and Neck Cancer (LiGeR - HN1)

Merus B.V.

NCT06525220

Recruiting Phase 2 496 target

A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma

Genmab

NCT05283720

Recruiting Phase 3 486 target

Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study

NRG Oncology

NCT07097142

Recruiting 480 target

Comparing the Effectiveness of Matched Related Donor Hematopoietic Stem Cell Transplantation to Disease Modifying Therapy in Pediatric Patients With Sickle Cell Disease

University of Rochester

NCT06941389

Recruiting NA 480 target

Disclosure Intervention for People in Treatment for Opioid Use Disorder

University of Delaware

NCT06458985

Recruiting Phase 2 474 target

Targeted Treatment for Metastatic Prostate Cancer, The PREDICT Trial

Alliance for Clinical Trials in Oncology

NCT06632977

Recruiting 460 target

Anesthetics and Analgesics in Children

Chi Dang Hornik

NCT03427736

Recruiting Phase 3 440 target

Evaluating the Efficacy and Safety of PT027 Compared With PT007 Administered As Needed in Participants 12 to < 18 Years of Age With Asthma

AstraZeneca

NCT06307665

Recruiting Phase 3 436 target

Fontan Udenafil Exercise Longitudinal Assessment Trial - 2

Mezzion Pharma Co.

NCT05918211

Recruiting Phase 3 421 target

Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients With Previously Untreated Mantle Cell Lymphoma

Alliance for Clinical Trials in Oncology

NCT05976763

Recruiting Phase 2 410 target

INBRX-106 in Combination With Pembrolizumab in First-line PD-L1 CPS≥20 HNSCC

Inhibrx Biosciences

NCT06295731

Recruiting Phase 3 408 target

A Study to Evaluate How Well Etavopivat Works in People With Sickle Cell Disease

Novo Nordisk A/S

NCT06612268

Recruiting Phase 3 400 target

Comparing Brief Behavioral Therapy (BBT-CI) and Healthy Eating Education Learning (HEAL) for Cancer-Related Sleep Problems While Receiving Cancer Treatment

University of Rochester NCORP Research Base

NCT04829539

Recruiting 400 target

Left Ventricular Structural Predictors of Sudden Cardiac Death

Johns Hopkins University

NCT01076660

Recruiting NA 400 target

Responding With Evidence and Access for Childhood Headaches

Children's Hospital Medical Center, Cincinnati

NCT05889624

Recruiting Phase 3 400 target

Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations

AstraZeneca

NCT07291037

Recruiting 400 target

A Multicenter Multinational Observational Study of Children With Hypochondroplasia

BioMarin Pharmaceutical

NCT06212947

Recruiting Phase 3 364 target

Testing the Addition of Total Ablative Therapy to Usual Systemic Therapy Treatment for Limited Metastatic Colorectal Cancer, The ERASur Study

Alliance for Clinical Trials in Oncology

NCT05673148

Recruiting NA 350 target

Oxytocin Rest to Reduce Cesarean Delivery

Christiana Care Health Services

NCT06268431

Recruiting NA 350 target

Testing eSCCIP: An eHealth Psychosocial Intervention for English and Spanish Speaking Parents of Children With Cancer

Nemours Children's Clinic

NCT05294302

Source: ClinicalTrials.gov (NIH/NLM) ClinicalTrials.gov AACT registry · 2026 Recruiting status is reported by each study's sponsor and mirrored from the public registry. Always confirm current eligibility and status on ClinicalTrials.gov before contacting a study.

Verify with NIH →